| |
NewswireToday - /newswire/ -
Holmes Chapel, Cheshire, United Kingdom, 09/02/2010 - Novozymes Biopharma will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at the 2010 BioProcess International Conference and Exhibition.
|
| |
Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will be showcasing its innovative portfolio of biopharmaceutical technologies and solutions at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition, 20-24 September at Rhode Island Convention Center, Providence, RI, USA.
The annual conference and exhibition aims to accelerate and improve biopharmaceutical processes and product development, attracting key personnel from across the bioprocessing industry. At this year’s event Novozymes’ booth will feature the company’s range of regulatory compliant, recombinant and animal-free products and technologies. These innovative solutions offer improved manufacturing efficiency, increased safety and result in superior final products.
During the five day conference, Novozymes will be presenting two technical posters entitled “Albumin: A robust pharmaceutical excipient in the stabilization of protein therapeutics’ and “Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production”. In addition the company will deliver a presentation on the “Impact of recombinant albumin on the stability of a malarial antigen vaccine”.
Novozymes will also be hosting a workshop on “Improving biomanufacturing efficiency through recombinant solutions”. Company experts will discuss how the introduction of innovative technologies and products and ongoing collaborative dialog with the biomanufacturing industry are driving efficiency improvements across the biopharmaceutical lifecycle.
The company will also be discussing its recent announcement of a 10-year extension to its joint agreement with SAFC®, a member of the Sigma-Aldrich® Group. The renewal sees SAFC retain exclusive marketing and distribution rights for Novozymes’ LONG ®R³IGF-I (LONG®R3) growth factor.
To learn more about the company’s biopharmaceutical technologies and solutions, please visit Novozymes at booth #507 and #509 at the 2010 BioProcess International Conference and Exhibition.
About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.
Novozymes’ natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Contacts:
Novozymes Biopharma
Sally Vernon, Customer Communications Manager
E: SYKE[.]novozymes.com.
Corporate Contacts:
Press and media:
Johan Melchior , T: +45 4446 0690, M: +45 3077 0690
René Tronborg
T: +45 4446 2274, M: +45 3077 2274
Paige Donnelly (USA)
T: +1 919 494 3209, M: +1 919 218 4501
Investor relations:
Tobias Bjørklund, T: +45 4446 8682, M: +45 3077 8682
Thomas Bomhoff (USA)
T: +1 919 494 3483, M: +1 919 649 2565
|
